We also reported novel FGFR fusion events in NSCLC patients, including SLC20A2-FGFR1, FGFR2-INA, and FGFR4-GAPGEFL1; thus, highlighting potential therapeutic targets for the management of such patients. Here, FGFR4 is linked to non-small cell lung carcinoma.